Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence

Background: The standard treatment for epithelial ovarian cancer (EOC) patients with advanced disease is carboplatin-paclitaxel combination therapy following initial debulking surgery, yet there is wide inter-patient variation in clinical response. We sought to identify pharmacogenomic markers relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fridley, Brooke L., Ghosh, Taraswi M., Wang, Alice, Raghavan, Rama, Dai, Junqiang, Goode, Ellen L., Lamba, Jatinder K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801852/
https://www.ncbi.nlm.nih.gov/pubmed/27047539
http://dx.doi.org/10.3389/fgene.2016.00037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4801852/
https://www.ncbi.nlm.nih.gov/pubmed/27047539
http://dx.doi.org/10.3389/fgene.2016.00037

Ejemplares similares